Intracellular SCARB2 mimicry overcomes decoy failure to broadly inhibit enteroviruses
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014699 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Shijin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, China. Hauptthemen laut MEDLINE: Receptors, Scavenger, Antiviral Agents, Lysosomal Membrane Proteins, Enterovirus Infections. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) are leading causes of severe hand, foot, and mouth disease (HFMD) with high childhood mortality and no specific antiviral therapy. SCARB2 is the essential uncoating receptor, yet extracellular SCARB2-Fc decoys fail to block infection, representing a decade-old paradox in enterovirus therapeutics. Here, we overcome this limitation by engineering RMP(R8), a cell-penetrating SCARB2 mimetic peptide comprising the minimal VP2-binding domain (W146-K166) fused to an octa-arginine transporter. RMP(R8) shows potent antiviral activity (EC 50 = 0.156 μg/mL), outstanding safety (selectivity index > 2003), and excellent aqueous solubility, a critical asset for clinical translation. It broadly inhibits genetically divergent EV-A71 isolates and CV-A16 in intestinal and neural cells by blocking viral entry. In a lethal neonatal mouse model, RMP(R8) increases survival against EV-A71 and CV-A16 challenge in vivo . Intracellular receptor mimicry thus establishes a generalizable strategy for viruses refractory to extracellular intervention. RMP(R8) is a promising clinical candidate to address the unmet need for targeted anti-enterovirus treatment, and our findings redefine how to drug virus-receptor interactions that act inside cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, China.
- Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, Jilin, China.
- Department of Respiration, Children's Medical Center, First Hospital, Jilin University, Changchun, Jilin, China.
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ZhejiangChina.
- Institute of Translational Medicine, Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin, China.
ORCID-Profile: Wei Wei
Förderung
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
Zitieren
APA
Wang, S., Tang, Y., Lai, S., Yang, J., Yang, Q., Liu, X., Yu, X. F., Guo, H., & Wei, W. (2026). Intracellular SCARB2 mimicry overcomes decoy failure to broadly inhibit enteroviruses. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014699
Vancouver
Wang S, Tang Y, Lai S, Yang J, Yang Q, Liu X, et al. Intracellular SCARB2 mimicry overcomes decoy failure to broadly inhibit enteroviruses. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014699
BibTeX
@article{Wang2026,
author = {Wang, Shijin and Tang, Yubin and Lai, Songyang and Yang, Jiaxin and Yang, Qingran and Liu, Xize and Yu, Xiao-Fang and Guo, Haoran and Wei, Wei},
title = {Intracellular SCARB2 mimicry overcomes decoy failure to broadly inhibit enteroviruses},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014699}
}
EUVIMED